칸디다질염 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1796911
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 칸디다질염 치료 시장 규모는 2024년에 9억 8,723만 달러로 평가되었고 예측 기간 중 CAGR은 4.52%를 나타내, 2030년에는 12억 8,716만 달러에 달할 것으로 예상됩니다.
세계의 칸디다질염 치료 시장은 새로운 항진균제의 개발과 세계 건강 관리 지출 증가로 큰 성장을 이루고 있습니다. 또한 고령자 증가와 함께 저비용으로 최상의 치료를 요구하는 수요 증가가 세계 각지에서 칸디다질염 치료 수요를 크게 늘리고 있습니다. 게다가 암, 심혈관질환, 신경질환, 당뇨병 등 만성질환의 유병률이 전 세계적으로 증가하고 있는 것도 칸디다질염 치료 수요를 높여 시장 성장을 가속할 것으로 예상됩니다. 또한, 위생 상태 유지에 대한 의식이 높아지고, 저비용으로 새로운 치료법을 사용할 수 있는 이점도 예측 기간 동안 칸디다질염 치료 시장을 더욱 뒷받침할 것으로 예상됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
9억 8,723만 달러
시장 규모 : 2030년
12억 8,716만 달러
CAGR : 2025-2030년
4.52%
급성장 부문
국소
최대 시장
북미
게다가, 동부균 감염에 의한 플루코나졸과 같은 광역 항생제의 사용 증가는 칸디다질염 치료 수요를 증가시키고 시장 성장을 지원할 것으로 예측됩니다. 이스트균 감염은 미국에서 세균성 질 감염에 이어 두 번째로 많은 질 감염입니다. 질 칸디다증의 외래 환자 수는 연간 140만 명으로 추정됩니다.
Global Vulvovaginal Candidiasis Treatment Market was valued at USD 987.23 Million in 2024 and is expected to reach USD 1287.16 Million by 2030 with a CAGR of 4.52% during the forecast period. The global market for Vulvovaginal Candidiasis Treatment is experiencing significant growth, driven by the growing development of new antifungal drugs and growing healthcare expenditure across the globe. Additionally, growing demand for the best treatment with low cost, along with growing geriatric population have significantly increased the demand for vulvovaginal candidiasis treatment across different parts of the globe. Additionally, increasing prevalence of chronic diseases like cancer, cardiovascular diseases, neurological diseases, and diabetes across the globe is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby fuelling the market growth. Besides, growing awareness on maintaining hygiene and benefits of using new treatments with lower cost is further expected to support the vulvovaginal candidiasis treatment market during the forecast period.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 987.23 Million
Market Size 2030
USD 1287.16 Million
CAGR 2025-2030
4.52%
Fastest Growing Segment
Topical
Largest Market
North America
Furthermore, increasing usage of broad-spectrum antibiotic such as Fluconazole because of yeast infection is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby supporting the market growth. It is the second most common type of vaginal infection after bacterial vaginal infections, in the United States. An estimated 1.4 million outpatient visits for vaginal candidiasis occur annually.
Key Market Drivers
Rising Prevalence of Vulvovaginal Candidiasis and Recurrent Infections
One of the primary drivers of growth in the global VVC treatment market is the rising prevalence of both acute and recurrent vulvovaginal candidiasis infections. Vulvovaginal candidiasis is caused predominantly by Candida albicans, and affects a large proportion of women worldwide, especially those of reproductive age. According to the Centers for Disease Control and Prevention (CDC), approximately 75% of all women will experience at least one episode of VVC during their lifetime, and nearly 40-45% of these individuals will experience two or more episodes. Around 5-8% of women are affected by recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more symptomatic episodes within a year. Several factors contribute to this high prevalence: increased antibiotic use, hormonal changes (due to pregnancy or contraceptives), diabetes, immunosuppression (including HIV/AIDS), and the growing use of immunosuppressive medications. The World Health Organization (WHO) notes that nearly 37.7 million people globally were living with HIV as of 2023, a key risk factor for fungal infections such as VVC.
The growing global awareness surrounding women's reproductive health, increased healthcare access, and proactive screening campaigns are further driving diagnosis rates, prompting a higher demand for effective antifungal therapies. Moreover, the global emphasis on sexual health and infection control, particularly in developing regions, has led to increased funding and outreach efforts aimed at early detection and treatment of fungal infections. Collectively, these trends underscore a growing need for both over the counter (OTC) and prescription treatments, fueling market expansion.
Key Market Challenges
Antifungal Resistance and Limited Treatment Efficacy
A significant challenge to the VVC treatment market is the increasing resistance to conventional antifungal drugs, particularly azoles. Repeated and often inappropriate use of azole antifungals such as fluconazole has led to decreased efficacy in many patients, especially those with recurrent vulvovaginal candidiasis (RVVC). Drug-resistant Candida species, including Candida glabrata and Candida auris, are becoming more prevalent and are often harder to treat. The World Health Organization (WHO), in its 2023 publication on fungal priority pathogens, classified Candida auris as a critical priority pathogen due to its high resistance profile, global spread, and association with severe healthcare outbreaks. The WHO has also recognized the urgent need for new antifungal drug development to address growing treatment gaps and antimicrobial resistance (AMR).
Furthermore, research by the Centers for Disease Control and Prevention (CDC) reveals that fluconazole resistance among Candida strains has increased steadily in recent years, complicating treatment decisions for physicians and leading to higher rates of treatment failure. This resistance is compounded by patient non-compliance, self-medication, and lack of definitive diagnostics, especially in low-resource settings. Addressing antifungal resistance requires substantial investment in surveillance, diagnostics, and antimicrobial stewardship programs. However, in many countries, such efforts remain underfunded or fragmented, hindering the timely management of resistant infections and posing a long-term threat to treatment efficacy and patient outcomes.
Key Market Trends
Shift Toward Novel and Non-Azole Antifungal Therapies
A significant trend in the VVC treatment market is the development and growing preference for non-azole antifungal therapies, particularly in cases of recurrent or drug-resistant infections. Traditional azole-based medications (like fluconazole, clotrimazole, and miconazole) have long been the mainstay for treating VVC. However, emerging drug resistance and the limited efficacy of azoles in recurrent infections have necessitated the development of novel antifungal agents. The shift is supported by increased research and regulatory momentum. For instance, the U.S. FDA approved ibrexafungerp, a novel triterpenoid antifungal agent, for the treatment of VVC in 2021. This new class of antifungals works differently from azoles, targeting the fungal cell wall rather than its membrane, offering a promising alternative for patients with azole-resistant candidiasis or intolerance to existing medications.
Government research institutions and funding agencies are also prioritizing antimicrobial resistance (AMR) and fungal infections. The CDC's Antibiotic Resistance Threats Report (2023) includes Candida species as serious threats, especially Candida auris, which is resistant to multiple antifungal drugs. As part of its response, the U.S. government is supporting antifungal drug development under initiatives such as the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB). This trend is likely to grow stronger as more patients and physicians seek effective treatment options for recurrent infections. Moreover, the pharmaceutical industry is investing in oral and topical agents that offer better bioavailability, fewer side effects, and resistance management-driving innovation in the market landscape.
Key Market Players
Astellas Pharma Inc.
Mycovia Pharmaceuticals, Inc.
Basilea Pharmaceutica Ltd.
Scynexis, Inc.
Grupo Ferrer Internacional, S.A.
Pfizer, Inc.
Pacgen Life Science Corporation
NovaDigm Therapeutics, Inc.
Cidara Therapeutics, Inc.
Amplyx Pharmaceuticals Inc.
Report Scope:
In this report, the Global Vulvovaginal Candidiasis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Vulvovaginal Candidiasis Treatment Market, By Drug Class:
Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others
Vulvovaginal Candidiasis Treatment Market, By Route of Administration:
Oral
Intravenous
Topical
Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Vulvovaginal Candidiasis Treatment Market, By Region:
North America
United States
Mexico
Canada
Europe
France
Germany
United Kingdom
Italy
Spain
Asia-Pacific
China
India
South Korea
Japan
Australia
South America
Brazil
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Vulvovaginal Candidiasis Treatment Market.
Available Customizations:
Global Vulvovaginal Candidiasis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Vulvovaginal Candidiasis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others)
6.2.2. By Route of Administration (Oral, Intravenous, Topical)
6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Market Map
6.3.1. By Drug Class
6.3.2. By Route of Administration
6.3.3. By Distribution Channel
6.3.4. By Region
7. North America Vulvovaginal Candidiasis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Vulvovaginal Candidiasis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. Canada Vulvovaginal Candidiasis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. Mexico Vulvovaginal Candidiasis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
8. Europe Vulvovaginal Candidiasis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Vulvovaginal Candidiasis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. Germany Vulvovaginal Candidiasis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. United Kingdom Vulvovaginal Candidiasis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. Italy Vulvovaginal Candidiasis Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Spain Vulvovaginal Candidiasis Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Vulvovaginal Candidiasis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Distribution Channel
9.3.2. India Vulvovaginal Candidiasis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Distribution Channel
9.3.3. Japan Vulvovaginal Candidiasis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Distribution Channel
9.3.4. South Korea Vulvovaginal Candidiasis Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Route of Administration
9.3.4.2.3. By Distribution Channel
9.3.5. Australia Vulvovaginal Candidiasis Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Class
9.3.5.2.2. By Route of Administration
9.3.5.2.3. By Distribution Channel
10. South America Vulvovaginal Candidiasis Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Vulvovaginal Candidiasis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Distribution Channel
10.3.2. Argentina Vulvovaginal Candidiasis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Distribution Channel
10.3.3. Colombia Vulvovaginal Candidiasis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Distribution Channel
11. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Route of Administration
11.2.3. By Distribution Channel
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Vulvovaginal Candidiasis Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Route of Administration
11.3.1.2.3. By Distribution Channel
11.3.2. Saudi Arabia Vulvovaginal Candidiasis Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Route of Administration
11.3.2.2.3. By Distribution Channel
11.3.3. UAE Vulvovaginal Candidiasis Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Route of Administration
11.3.3.2.3. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. Porters Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products/Services
15. SWOT Analysis: Global Vulvovaginal Candidiasis Treatment Market
